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Letter to the Editor
ovel genetic variants linked to coronary artery disease by genome-wide association are not associated with carotid
rtery intima-media thickness or intermediate risk phenotypes
bstract
ackground: It is uncertain whether the novel single nucleotide polymorphisms (SNPs) that have recently been associated with coronary
rtery disease (CAD) in genome-wide studies also influence carotid atheroma and stroke risk. The mechanisms of their association with CAD
re unknown; relationships to other cardiovascular phenotypes may give mechanistic clues. Carotid artery intima-media thickness (CIMT)
s a subclinical marker of atherosclerosis associated with stroke. We investigated association of reported CAD risk variants with CIMT, and
ith other intermediate phenotypes that may implicate causative pathways.
ethods: We studied 1425 members of 248 British Caucasian families ascertained through a hypertensive proband. We genotyped CAD risk
NPs on chromosomes 9 (rs1333049, rs7044859, rs496892, rs7865618), 6 (rs6922269) and 2 (rs2943634) using TaqMan. Merlin software
as used for family-based association testing.
esults: No significant association was found between genotype at any SNP and CIMT in 846 individuals with acceptable measurements.
or were SNPs significantly associated with blood pressure, obesity, cholesterol, CRP, interleukin-6, TNF-, or leptin.
onclusions: These novel CAD variants are not associated with CIMT and do not appear to mediate the risk of atherothrombosis through
nown risk factors.
2008 Elsevier Ireland Ltd.
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. Background
A number of common single nucleotide polymorphisms
SNPs) have been robustly associated with coronary artery
isease (CAD) in recent genome-wide studies [1–3], but,
n contrast to previous associations derived from candidate
ene analyses, the mechanisms underlying the associations
ith CAD are unknown. A relationship of these variants
o other intermediate cardiovascular phenotypes may give
mportant mechanistic clues. Carotid artery intima-media
hickness (CIMT) is a subclinical marker of atherosclerosis
ssociated with stroke [4]. Blood pressure, plasma choles-
erol and obesity are established cardiovascular risk factors,
hile plasma levels of interleukin-6 (IL-6), tumour necrosis
actor- (TNF-), C-reactive protein (CRP), and leptin have
lso been implicated in atherogenesis [5].
We determined whether these novel CAD risk variants
re associated with carotid atheroma, assessed by CIMT,
nd other intermediate risk markers which might implicate
ausative pathways, in a large panel of extended families
hat has been shown to have adequate power to detect small
enetic influences on quantitative traits, including CIMT [6].
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021-9150 © 2008 Elsevier Ireland Ltd.
oi:10.1016/j.atherosclerosis.2008.06.025
Open access under CC BY-NC-ND license.. Methods
.1. Participants
1425 members of 248 British Caucasian families were
scertained through hypertensive probands and phenotyped
or a quantitative genetic study of cardiovascular risk factors
rom 1993 to 2001. The local ethics committee approved the
tudy; the detailed ascertainment strategy has been described
reviously [6]. A clinical history, body mass index (BMI),
aist–hip ratio (WHR), 24-hour ambulatory blood pressure
ecordings, and blood samples were obtained. Bilateral com-
on carotid ultrasonography and CIMT measurement was
erformed in a subset of 953 participants, as previously
escribed [6]. Levels of plasma IL-6, TNF-, high-sensitivity
RP, leptin and total non-fasting cholesterol were measured
sing commercially available assays..2. Genotyping
The chromosome 9p21.3 region associated with CAD
n previous genome-wide studies consists of two haplotype
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Fig. 1. Linkage disequilibrium and minor allele frequencies of typed SNPs.
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locks which can be tagged in Caucasian populations
ith three SNPs from block 1 (rs7044859, rs496892 and
s7865618) and one SNP from block 2 (rs1333049) [3,7]. We
herefore genotyped these four SNPs in that region. We also
enotyped the lead SNPs most strongly associated with CAD
n previous studies on chromosome 6q25.1 (rs6922269)
nd chromosome 2q36.3 (rs2943634) [3]. All SNPs were
enotyped using TaqMan. Mendelian inheritance and
orrespondence of genotype frequencies to Hardy–Weinberg
roportions was checked using PEDSTATS [8].
.3. Statistical analysis
Phenotypes were examined for normality and log-
ransformed if required. Adjustments were made for
ignificant covariates determined by linear regression, con-
idering age, sex, cardiovascular medications, smoking
tatus (current/former/never), alcohol consumption (units per
eek) and exercise habit (frequency per week). Association
etween genotypes and adjusted phenotypes was assessed
sing Merlin v1.1.2 [9]. This evaluates the evidence for asso-
iation under an additive genetic model, which was selected
n view of the data from previous publications showing
lear trends in CAD risk between different genotypes at
hese SNPs (i.e. heterozygotes having CAD risk interme-
iate between high-risk and low-risk homozygotes) [3]. In
rder to estimate the upper bound of the genetic effect that
s plausibly associated with each SNP for each phenotype,
inear regression models (with robust “sandwich” variance
stimation to compensate for family clustering) were fitted
o model additive genetic effects using StataTM9.2. Narrow-
ense heritability estimates (and 95% confidence intervals
hereof) were calculated by standard population genetic
ormulae.
. Results1425 participants were included: mean age 49.5 (±15.5)
ears, 747 (52.4%) female. General characteristics of the
tudy participants are shown in Table 1.
o
m
a
r
able 1
eneral characteristics of the study population
haracteristic N
revious ishemic heart disease 61/142
revious stroke 33/142
revious peripheral vascular disease 13/142
iabetes 35/142
urrent or former smoker 507/14
ypertension 512/14
aytime systolic blood pressure (mmHg) 958
aytime diastolic blood pressure (mmHg) 958
lasma total cholesterol (mmol/l) 1289
MI (kg/m2) 1402
HR 1357iamond the D’ (on top) and r2 values (on bottom) for typed SNP combina-
ions in our population. mAF = Minor allele frequency.
854 participants had measurable CIMT, as shown in
able 2. Median maximal CIMT values of 0.858 mm in men
nd 0.803 mm in women were within the normal population
ange (0.36–1.07 mm).
Genotyping was complete for more than 95% of the 1393
articipants with DNA available at all loci. Allele frequen-
ies and linkage disequilibrium for typed SNPs are shown
n Fig. 1; these were similar to the HapMap CEU popula-
ion and did not deviate significantly from Hardy–Weinberg
roportions.
There was no significant association between genotype
nd covariate-adjusted log-transformed maximal CIMT at
he loci studied. Neither was there evidence of a significant
ssociation between genotypes and plasma cholesterol, CRP,
L-6, TNF-, or leptin concentrations; nor clinical measure-
ents of blood pressure, BMI or WHR (using a globalp-value
f p = 0.05, adjusted for multiple testing). The upper bound
f the contribution to the total population variance in maxi-
al CIMT was between 0.7% and 1.4% for the typed SNPs,
nd of a similar order for the other traits tested (Table 2,
ight-hand column).
Median (interquartile range)
5 (4.3%) –
5 (2.3%) –
5 (0.9%) –
5 (2.5%) –
25 (35.6%) –
25 (35.9%) –
131 (121.1–144.1)
78.6 (72.0–88.0)
5.6 (4.8–6.4)
25.4 (23.1–28.2)
0.85 (0.78–0.91)
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Table 2
Risk phenotypes in the study population and estimated maximum genetic effect on total phenotypic variance for the typed SNPs
Variable N Median (interquartile range) Maximum genetic effect for typed SNPsa
BMI (kg/m2)b 1402 25.4 (23.1–28.2) 0.4–1.7%
WHR 1357 0.85 (0.78–0.91) 0.6–1.4%
Daytime systolic blood pressure (mmHg)b 958 131 (121.1–144.1) 0.5–0.7%
Mean CIMT (mm)b 854 0.76 (0.65–0.91) 0.7–1.5%
Max CIMT (mm)b 856 0.83 (0.71–1.00) 0.7–1.4%
Plasma total cholesterol (mmol/l)b 1289 5.6 (4.8–6.4) 0.5–1.4%
Plasma IL-6 (pg/ml)b 1186 0.78 (0.48–1.38) 0.4–0.7%
Plasma TNF- (pg/ml)b 1186 0.74 (0.35–1.66) 0.6–1.3%
Plasma CRP (mg/l)b 1314 1.40 (0.55–3.2) 0.4–1.7%
Plasma Leptin (ng/l)b 1319 8.6 (4.6–15.3) 0.5–1.0%
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t
ka Numbers represent the range of maximum plausible genetic contribution
b Variables log-transformed before analysis to approximately normalise th
A stepwise backward-elimination multivariate regression
rocedure failed to find any multilocus models showing asso-
iation (removal p-value > 0.2) to the CIMT phenotype. This
s a powerful approach for examining tightly linked SNPs in
ssociation models that avoids the computational complexity
nd degrees of freedom that accompany a formal haplotype
nalysis [10]. It is therefore unlikely that chromosome 9p21
aplotypes are associated with CIMT, recognising that the
ower to detect subtle associations is very low for minor
aplotypes with frequencies < 5%.
. Discussion
The lack of association with CIMT measurements sug-
ests that these novel SNPs, while convincingly associated
ith CAD risk, do not influence development of carotid
therosclerosis. Our findings extend the results of a recent
tudy that found no significant association between a SNP
ssociated with CAD risk on chromosome 9 (rs10757278, for
hich rs1333049 we typed is a perfect proxy) and ischemic
troke, once potentially-confounding cases of known CAD
ere excluded from the analysis [11].
The lack of association with intermediate biochemical and
linical phenotypes associated with atherosclerosis (includ-
ng inflammatory markers) extends the findings of two
revious studies which found no association between CAD
isk variants on chromosome 9 (in strong linkage disequi-
ibrium with the SNPs we typed, r2 > 0.8) and risk factors
ncluding blood pressure, BMI, cholesterol and glucose [2];
or with biochemical parameters including lipoprotein(a),
brinogen, albumin, bilirubin and homocysteine [12].
The maximum plausible genetic effect for the typed SNPs
n CIMT and the other phenotypes, which we calculated
ased on the observed mean effect and 95% confidence inter-
al, was low in all cases. Therefore, although this study cannot
xclude any effect of the typed SNPs on these phenotypes, it
emonstrates that such effects could only be of small mag-
itude, and are unlikely to be clinically significant. Selection
hrough hypertensive probands could potentially introduce
ias if there were an interaction between hypertension and
C
rl phenotypic variance of each trait for typed SNPs.
butions.
he variants studied, but only 36% of the participants were
ypertensive and the variants did not associate with hyper-
ension. On the other hand, ascertainment for hypertension, a
rait strongly related to cardiovascular risk, resulted in selec-
ion of individuals with mean CIMT 33% higher than the
eneral population, which should increase the power for the
etection of variants with small effects.
CIMT has been commonly used as a surrogate marker
or atherosclerosis [13,14]. It is associated with cardiovas-
ular disease risk factors and is an independent predictor
f atherosclerosis and clinical outcomes including stroke
4,15]. CIMT progression may be reduced or reversed with
nterventions that reduce the risk of future cardiovascular
vents, supporting the concept that CIMT measurement can
e used as a marker for atherosclerosis [15]. Although a
lose association between CIMT and carotid plaques has
een demonstrated [16], however, increased CIMT is not
ynonymous with carotid atheroma [15]. A potential limi-
ation of this study is that the presence of carotid plaque,
hich is more specific for atherosclerosis, was not directly
ssessed.
We examined SNP associations with a number of inter-
ediate phenotypes to identify causative pathways through
hich genotypes at these SNPs influence risk. No associa-
ions were found, suggesting that the effects are mediated
hrough unknown pathways. Further investigations will be
equired to determine the mechanisms by which these SNPs
re associated with CAD.
. Conclusion
These novel CAD variants are not associated with varia-
ion in CIMT and do not appear to mediate CAD risk through
nown risk factors.onﬂict of interest
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